Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serena Lacerenza

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancers|May 6, 2020
<i>CUL4A</i>, <i>ERCC5</i>, and <i>ERCC1</i> as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) StudyDavid S Moura, Paloma Sanchez-Bustos, Antonio Fernandez-Serra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC TrialDavid S Moura, Jesus M Lopez-Marti, Iva Benesova, et al.
Molecular Oncology|May 13, 2021
A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedinDavid S Moura, Maria Peña-Chilet, Juan Antonio Cordero Varela, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancers|May 6, 2020
<i>CUL4A</i>, <i>ERCC5</i>, and <i>ERCC1</i> as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) StudyDavid S Moura, Paloma Sanchez-Bustos, Antonio Fernandez-Serra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC TrialDavid S Moura, Jesus M Lopez-Marti, Iva Benesova, et al.
Molecular Oncology|May 13, 2021
A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedinDavid S Moura, Maria Peña-Chilet, Juan Antonio Cordero Varela, et al.
Pageof 2